NCT06402331 2026-04-08
AlphaBreak
Fusion Pharmaceuticals Inc.
Phase 2 Active not recruiting
Clinical Trials
73 trialsNCT06909825 2026-04-08
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Fusion Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT02044354 2026-04-01
CABA-DOC
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Completed
NCT04853498 2026-03-31
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Terminated
NCT06193486 2026-03-31
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT06401980 2026-03-30
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Phase 2 Recruiting
NCT06052306 2026-03-19
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer
Phase 1 Active not recruiting
NCT07476001 2026-03-17
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05171816 2026-03-11
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
AstraZeneca
Phase 3 Active not recruiting
NCT04109729 2026-03-02
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
NCT05125016 2026-02-27
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06533644 2026-02-27
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Syncromune, Inc.
Phase 2 Recruiting
NCT04754191 2026-02-12
ENCORE
University of Utah
Phase 2 Active not recruiting
NCT07244341 2026-02-04
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Daiichi Sankyo
Phase 1 Recruiting
NCT03732820 2026-01-29
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT06492122 2026-01-29
ProTACT
Full-Life Technologies GmbH
Phase 1 Recruiting
NCT07365995 2026-01-26
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3 Not yet recruiting
NCT05570994 2026-01-08
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
British Columbia Cancer Agency
Phase 1/2 Enrolling by invitation
NCT06866938 2026-01-06
ReaLuP
Hospices Civils de Lyon
Phase 2 Recruiting
NCT06514521 2025-12-30
Post Marketing Study on Pluvicto in Korea
Novartis
Recruiting
NCT06380738 2025-12-26
PROceed
AstraZeneca
Recruiting
NCT06155084 2025-12-22
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Hinova Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT06228053 2025-12-22
SYNERGY-201
Syntrix Biosystems, Inc.
Phase 2 Recruiting
NCT05457257 2025-12-19
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Completed
NCT06568562 2025-12-09
PRO-XL
University of Utah
Phase 2 Recruiting
NCT05682443 2025-12-02
PRESERVE-006
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT06029998 2025-11-28
BORXPTEN
University of Utah
Phase 2 Recruiting
NCT06100705 2025-11-04
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Yale University
Phase 2 Recruiting
NCT05613894 2025-10-31
CaboLu
University of Utah
Phase 1 Recruiting
NCT06031805 2025-10-28
PROWESs
AstraZeneca
Recruiting
NCT02141438 2025-10-16
REASSURE
Bayer
Completed
NCT05603559 2025-10-03
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT04158245 2025-09-22
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies
Tulane University
Phase 2 Completed
NCT07172126 2025-09-15
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Not yet recruiting
NCT05544227 2025-07-23
Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer
Williams Cancer Foundation
Phase 1 Completed
NCT05401214 2025-06-13
Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)
Janssen Research & Development, LLC
Approved for marketing
NCT06383052 2025-05-21
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Norroy Bioscience Co., LTD
Phase 1/2 Active not recruiting
NCT04253262 2025-05-04
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
Brown University
Phase 1/2 Active not recruiting
NCT06480110 2025-04-13
Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Rigshospitalet, Denmark
Phase 1/2 Recruiting
NCT05340374 2025-04-06
LuCAB
Peter MacCallum Cancer Centre, Australia
Phase 1/2 Active not recruiting
NCT06250244 2024-12-11
177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT04060394 2024-10-10
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
Laekna Limited
Phase 1/2 Completed
NCT05116579 2024-09-05
Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Sun Yat-sen University
Recruiting
NCT04629781 2024-08-01
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
Swiss Cancer Institute
Phase 1 Terminated
NCT06529549 2024-07-31
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
Sun Yat-sen University
Recruiting
NCT05613738 2024-07-10
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
Peking Union Medical College Hospital
Phase NA Recruiting
NCT03770455 2024-07-09
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
Tulane University
Phase 2 Terminated
NCT05762536 2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2 Recruiting
NCT05458544 2024-04-29
LUCIDA
FutureChem
Phase 1/2 Recruiting
NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed